FF
FFEA.F Faes Farma S.A
- Market cap
- EUR 1.52B
- P/E
- 18.0x
- P/B
- 1.96x
- ROE
- 10.7%
- Dividend yield
- 3.68%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is FFEA.F undervalued?
Graham numberFFEA.F trades 25.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Faes Farma S.A fundamental analysis
No fundamental analysis for Faes Farma S.A yet.
Faes Farma S.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Faes Farma S.A
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants services, as well as acquiring, purchasing, disposing of, investing in, holding, using…
Full company profileFaes Farma S.A financial statements
Faes Farma S.A annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 229M | 275M | 324M | 357M | 380M | 399M | 439M | 451M | 494M | 610M |
| Gross Profit | 151M | 178M | 204M | 227M | 240M | 252M | 282M | 297M | 327M | 396M |
| Operating Income | 48.2M | 50.7M | 62.6M | 75.5M | 92.6M | 98.9M | 102M | 104M | 110M | 91.1M |
| EBITDA | - | 58.2M | 72.2M | 90.9M | 100.0M | 110M | 121M | 123M | 128M | 120M |
| Net Income | 36.6M | 42.2M | 51.6M | 64.0M | 72.5M | 83.2M | 89.6M | 91.9M | 111M | 79.6M |
| EPS | - | 0.16 | 0.19 | 0.23 | 0.26 | 0.28 | 0.28 | 0.30 | 0.36 | 0.26 |
| Balance Sheet | ||||||||||
| Total Assets | 331M | 430M | 481M | 494M | 564M | 642M | 726M | 776M | 853M | 1.34B |
| Total Liabilities | 46.3M | 109M | 121M | 80.0M | 91.3M | 104M | 123M | 113M | 126M | 596M |
| Shareholders' Equity | 285M | 320M | 360M | 413M | 471M | 537M | 601M | 662M | 726M | 745M |
| Cash & Short-term Investments | 58.8M | 43.3M | 76.0M | 52.9M | 91.2M | 70.3M | 66.4M | 34.6M | 64.2M | 117M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 49.6M | 41.7M | 59.3M | 67.6M | 78.5M | 79.6M | 107M | 101M | 115M | 78.5M |
| Capital Expenditure | 12.0M | 12.1M | 12.7M | 17.0M | 20.2M | 51.5M | 75.2M | 102M | 39.5M | 23.6M |
| Free Cash Flow | - | 25.1M | 46.7M | 46.2M | 52.8M | 20.2M | 25.8M | -1.22M | 75.9M | 54.8M |
| Ratios | ||||||||||
| ROE | 12.8% | 13.2% | 14.3% | 15.5% | 15.4% | 15.5% | 14.9% | 13.9% | 15.3% | 10.7% |
| ROA | 11.0% | 9.8% | 10.7% | 13.0% | 12.9% | 13.0% | 12.3% | 11.8% | 13.1% | 5.9% |
| Net Profit Margin | 16.0% | 15.4% | 15.9% | 17.9% | 19.1% | 20.9% | 20.4% | 20.4% | 22.6% | 13.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Faes Farma S.A dividends
- Dividend yield
- 3.68%
- Forward dividend
- 0.13 EUR
- Payout ratio
- 70.0%
- Ex-dividend date
- Jul 2, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 55.7M | 0.18 | 70.0% |
| 2024 | EUR 48.2M | 0.16 | 43.3% |
| 2023 | EUR 14.6M | 0.05 | 15.9% |
| 2022 | EUR 7.44M | 0.02 | 8.3% |
| 2021 | EUR 4.93M | 0.02 | 5.9% |
| 2020 | EUR 4.24M | 0.02 | 5.8% |
| 2019 | EUR 4.31M | 0.02 | 6.7% |
| 2018 | EUR 7.55M | 0.03 | 14.6% |
| 2017 | EUR 6.28M | 0.02 | 14.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 27:26 on Apr 12, 2023.
Who owns Faes Farma S.A
- Insiders 20.35%
- Institutions 15.71%
- Public & others 63.94%
- Shares outstanding 311M
- Free float 218M
Faes Farma S.A company profile
- Company name
- Faes Farma S.A
- Ticker
- FFEA.F
- ISIN
- ES0134950F36
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,677
- Fiscal year end
- December
- Address
- Avenida AutonomIa 10, Leioa, Spain, 48940
- Phone
- 34 944 81 83 00
- Website
- faesfarma.com
About Faes Farma S.A
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants services, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. The company also provides animal nutrition and health products. It offers products for various therapeutic areas. Faes Farma, S.A. was incorporated in 1933 and is headquartered in Leioa, Spain.
Faes Farma S.A management
10- Mr. Eduardo Recoder de la CuadraCEO & Executive Director
- Mr. Iker Etxezarreta FraileChief Financial Officer
- Ms. Isabel NajeraChief Scientific & Medical Officer
- Ms. Maria MarinHead of Investor Relations & External Communication
- Mr. Alberto Fernández FernándezChief Marketing & Portfolio Strategy Officer
- Mr. Carlos Gutierrez AgueroChief People Officer
- Mr. Xavier ArnaudChief Business Development Officer
- Mr. Jose Luis Diaz CapoteChief International Business Officer
- Ms. Mariana Soroa ZubiriaChief GRC & Internal Audit Officer
- Mr. German Fernandez-CanodíazChief Farm Faes Business Officer